MU's long-term customer deals lock in volumes and pricing, improving demand visibility and softening earnings swings through future memory cycles.
Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript
Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials.
| Capital Markets Industry | Financials Sector | - CEO | BVC Exchange | US38747T4849 ISIN |
| US Country | - Employees | 9 Sep 2026 Last Dividend | - Last Split | - IPO Date |